Arrowhead Pharmaceuticals (ARWR) EBT Margin (2010 - 2026)
Arrowhead Pharmaceuticals' (ARWR) quarterly EBT Margin came in at 186.56% in Q1 2026, down 25467.0% YoY from N/an in Q1 2025, and down 1842.37% on a QoQ basis from 10.71% in Q4 2025.
Powered by 
Analysis
Arrowhead Pharmaceuticals (ARWR) EBT Margin (2010 - 2026) Analysis & Trends
Arrowhead Pharmaceuticals (ARWR) has 17 years of EBT Margin data on file, last reported at 186.56% in Q1 2026.
- Quarterly EBT Margin fell 25467.0% year-over-year to 186.56% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 40.56% (down 1263.0% YoY) and the FY2025 annual result came in at 6.21%, up 1725375.0% from the prior year.
- EBT Margin retreated to 186.56% in Q1 2026, from 10.71% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 68.11% in Q1 2025 to a low of 7004.6% in Q4 2024.
- A 5-year average of 961.91% and a median of 204.42% in 2022 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2023 — EBT Margin slumped 383881 bps — and 2025, when it soared 701531 bps.
- Tracing ARWR's EBT Margin over 5 years: stood at 66.82% in 2022, then tumbled by 5745 bps to 3905.63% in 2023, then slumped by 79 bps to 7004.6% in 2024, then soared by 100 bps to 10.71% in 2025, then plunged by 1842 bps to 186.56% in 2026.
- The last three EBT Margin figures came in at 186.56% (Q1 2026), 10.71% (Q4 2025), and 14.08% (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Arrowhead Pharmaceuticals | 12.40 Bn | 10.80 Bn | - | -237.74% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -237.74% |
| Mar 31, 2026 | -186.56% |
| Dec 31, 2025 | 10.71% |
| Sep 30, 2025 | 14.08% |
| Jun 30, 2025 | -644.97% |
| Mar 31, 2025 | 68.11% |
| Dec 31, 2024 | -7,004.60% |
| Dec 31, 2023 | -3,905.63% |
| Sep 30, 2023 | -677.08% |
| Jun 30, 2023 | -653.29% |
| Mar 31, 2023 | 32.60% |
| Dec 31, 2022 | -66.82% |
| Sep 30, 2022 | -260.20% |
| Jun 30, 2022 | -222.28% |
| Mar 31, 2022 | 29.23% |
| Dec 31, 2021 | -229.13% |
| Sep 30, 2021 | -165.54% |
| Jun 30, 2021 | -65.21% |
| Mar 31, 2021 | -81.73% |
| Dec 31, 2020 | -97.32% |